Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Strong Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Avenue Therapeutics, Inc. Common Stock (ATXI)

Pharmaceutical Preparations

https://www.avenuetx.com

Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule for CNS diseases, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.

1111 KANE CONCOURSE, SUITE 301
BAY HARBOR ISLANDS, FL

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/27/2017

Market Cap

2,380,695

Shares Outstanding

13,250,000

Weighted SO

13,247,622

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

HOTH --.--%

REVB --.--%

NRBO --.--%

VRAX --.--%

PBLA --.--%

PALI --.--%

QNRX --.--%

CFRX --.--%

ALLR --.--%

Beta

-0.1960

Last Div

0.0000

Range

2.25-75.0

Chg

0.0100

Avg Vol

46591

Mkt Cap

2380695

Exch

NASDAQ

Country

US

Phone

781 652 4500

DCF Diff

-8.2256

DCF

12.6256

Div Yield

0.0000

P/S

0.0000

EV Multiple

0.2368

P/FV

0.5936

Div Yield %

0.0000

P/E

-0.2730

PEG

0.0000

Payout

0.0000

Current Ratio

4.2963

Quick Ratio

4.2963

Cash Ratio

4.2369

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

0.0000

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

-0.7565

ROA

-2.0770

ROE

-7.4910

ROCE

-2.8006

NI/EBT

1.7539

EBT/EBIT

0.5511

EBIT/Rev

0.0000

Debt Ratio

0.0000

D/E

0.0000

LT Debt/Cap

0.0000

Total Debt/Cap

0.0000

Int Coverage

32.2831

CF/Debt

0.0000

Equity Multi

1.0470

Rec Turnover

0.0000

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-7.6814

FCF/Share

-5.8921

Cash/Share

4.4007

OCF/Sales

0.0000

FCF/OCF

0.7671

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

-4.2930

Div&CapEx Cov

-4.2930

P/BV

0.5936

P/B

0.5936

P/S

0.0000

P/E

-0.2730

P/FCF

-0.3615

P/OCF

-0.3294

P/CF

-0.3294

PEG

0.0000

P/S

0.0000

EV Multiple

0.2368

P/FV

0.5936

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 05, 09:15 Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds GlobeNewswire Inc. Jan 04, 08:30 Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol GlobeNewswire Inc. Jan 02, 08:30 Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) GlobeNewswire Inc. Dec 01, 08:30 Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting GlobeNewswire Inc. Nov 02, 15:00 Avenue Therapeutics Announces Closing of $5.0 Million Public Offering GlobeNewswire Inc. Oct 31, 09:15 Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering

Revenue Product Segmentation